Jiangsu Hansoh Pharmaceutical Co., Ltd.
41 active trials across 9 therapeutic areas
41
Active Trials
30
Phase 1
9
Phase 2
6
Phase 3
9
Therapeutic Areas
Portfolio Concentration: 85% of active trials in Oncology
Oncology
35 active / 36 total
NSCLC
11 active
3 Ph3
11 total since 2015
Solid Tumor (Advanced)
6 active
7 total since 2015
CML
3 active
3 total since 2015
Renal Cell Carcinoma
2 active
2 total since 2015
Ovarian Cancer
2 active
2 total since 2015
Breast Cancer
2 active
2 total since 2015
Colorectal Cancer
2 active
2 total since 2015
Bladder Cancer
1 active
1 total since 2015
Lung Cancer (General)
1 active
1 total since 2015
Triple Negative Breast Cancer
1 active
1 total since 2015
Prostate Cancer
1 active
1 total since 2015
Gastric Cancer
1 active
1 total since 2015
Pancreatic Cancer
1 active
1 total since 2015
SCLC
1 active
1 total since 2015
Metabolic
5 active / 8 total
Immunology
3 active / 4 total
Infectious Disease
1 active / 2 total
Rare Disease
1 active / 1 total
Women's Health
1 active / 1 total
CNS
0 active / 2 total
Musculoskeletal
0 active / 1 total
Renal
0 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)